Episode Details

Back to Episodes
Lilly’s Zepbound Cuts Risk of Diabetes

Lilly’s Zepbound Cuts Risk of Diabetes

Published 1 year, 4 months ago
Description

Watch Alix and Paul LIVE every day on YouTube: http://bit.ly/3vTiACF. 

Sam Fazeli, Bloomberg Intelligence, Director of Research for Global Industries and Senior Pharmaceuticals, discusses how Eli Lilly’s drug Zepbound, cuts the risk of diabetes. Craig Trudell, Bloomberg Global Autos Editor, discusses the European Union saying it plans to introduce an additional 9% tariff on Teslas imported from China. Dryden Pence, CIO at Pence Wealth Management, joins to discuss his outlook for the markets. Henri Pierre-Jacques, Co-founder & Managing Partner, at Harlem Capital Partners, discusses current investments in AI. Katerina Simonetti, Senior Vice President, Private Wealth Advisor of Morgan Stanley Private Wealth Management, discusses her outlook on the markets, investing.

Hosts: Paul Sweeney and Alix Steel

See omnystudio.com/listener for privacy information.

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us